For 2025, Edwards Lifesciences (NYSE:EW) projects constant currency sales growth of 8% to 10%, with adjusted EPS between $2.40 and $2.50. Transcatheter Aortic Valve Replacement sales are expected ...

"It was a chance for a young guy to get a lot of responsibility," retired Edwards Lifesciences CEO Mike Mussallem said in an ...

the Transcatheter Aortic Valve Replacement ("TAVR") platform. More specifically, throughout the Class Period, Edwards Lifesciences repeatedly assured investors that its TAVR platform was ...

US medical device giant Edwards Lifesciences has said patients ... in improved one-year survival after transcatheter aortic valve replacement versus prior generation valves, given it reduces ...

He has also acted as a Consultant for Sorin and received research support from Edwards Lifesciences. Jean G. Dumesnil received Speakers' Bureau honoraria from Medtronic and St Jude Medical.

Major Growth Drivers Transcatheter Aortic Valve Replacement (TAVR ... Surgical Therapies: Edwards plans to expand the adoption of its RESILIA portfolio, which includes innovative solutions ...

There was free aortic regurgitation because of dilatation of the valvular annulus; the cusps themselves were not deformed. The valve was excised and a No. 9 Starr-Edwards valve inserted.

Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences' disclosures about its core product, the Transcatheter Aortic ...

the Transcatheter Aortic Valve Replacement (“TAVR”) platform. More specifically, throughout the Class Period, Edwards Lifesciences repeatedly assured investors that its TAVR platform was ...